OSE Immunotherapeutics & HalioDx to partner in Tedopi® Phase 3 trial

The two firms would focus on analyzing and testing the clinical biopsy tissue samples from subjects participating in the Phase 3 Atalante 1 clinical study, currently under progress.

OSE Immunotherapeutics, a clinical-stage biotechnology company dedicated towards the development of novel immunotherapies, has recently joined forces with immuno-oncology diagnostic company, HalioDx.

As per sources, the collaboration aims on a translational study of immune biomarkers, as part of the ongoing Phase 3 clinical study of neoepitope combination Tedopi® in NSCLC (nonsmall cell lung cancer) patients. The duo would primarily focus on the analysis and testing of clinical biopsy tissue cases from patients currently participating in the Phase 3 Atalante 1 clinical trial.

With this tie-up, HalioDx will utilize its know-how in registered technology immuno-oncology diagnostic platforms to undertake immune biomarker exploratory work as part of the clinical trial objectives.

According to Alexis Peyroles, CEO, OSE Immunotherapeutics, their firm is looking forward to integrating HalioDx’s pioneering diagnostic applications like Immunosign® and Immunoscore® with OSE's neoepitope combination Tedopi® to conduct a translational investigation focused on detecting potential immune biomarkers in NSCLC.

As for the data generated, OSE aims at defining patient’s responder profile to Tedopi® treatment in advanced lung cancer, said Peyroles.

Incidentally, the collaboration comes in line with OSE’s recently announced new clinical and preclinical results on Tedopi® and the BiCKI® platform at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Reportedly, the results presented at the event demonstrated that the survival to advanced NSCLC which was significantly prolonged in patients immunized with the combination of neoepitopes used in Tedopi®

Speaking on which, Peyroles said that the results from translational analysis exhibit that neoepitope combination Tedopi® improves the cancer cells detection by antigen-specific CD8 T cells with a favorable correlation with patients’ survival.

He added that their firm is encouraged by these findings and is looking forward to validating the correlation between neoepitope response and patient survival in further translational studies.

Source Credit: https://ose-immuno.com/wp-content/uploads/2019/11/EN_191127_HalioDx-Tedopi.pdf